First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration
Pharmaceutics · 27.03.2024 · 16 (4) · 470
DOI: 10.3390/pharmaceutics16040470 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 27.03.2024. Verfasst von Wissam Aljundi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Saarland University Medical Center UKS, 66421 Homburg/Saar, Germany. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
To evaluate the outcomes of intravitreal faricimab (IVF) for refractory neovascular age-related macular degeneration (nAMD) and investigate the impact of baseline optical coherence tomography, biomarkers for total IVF injections are needed.
Methods
A retrospective analysis of 33 eyes of patients who completed one year (52 W) of treatment with IVF. The eyes received four IVF injections (6 mg/0.05 mL) as the upload phase. Thereafter, the treatment interval was extended to 8 or 12 weeks if disease activity was not recorded. The outcome measures included best-corrected visual acuity (BCVA), central macular thickness (CMT), subfoveal choroidal thickness (SFCT), and retinal fluid distribution.
Results
A total of 33 eyes were included. CMT decreased significantly at 52 W (p < 0.01). BCVA and SFCT did not change significantly at 52 W (p > 0.05). The number of eyes with subretinal fluid decreased significantly at 52 W (p < 0.01). Complete fluid resolution was achieved in 20 eyes (60%). The total number of injections was significantly negatively correlated with the presence of hyperreflective dots at baseline (HRDs, p < 0.01) and SFCT at baseline (p < 0.01).
Conclusions
IVF led to a significant reduction in CMT with stabilization of BCVA. The total number of injections was lower in eyes with HRDs and increased SFCT at baseline. This might provide clues regarding response to IVF for future studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Saarland University Medical Center UKS, 66421 Homburg/Saar, Germany.
ORCID-Profile: Wissam Aljundi, Berthold Seitz, Alaa Din Abdin
Zitieren
APA
Aljundi, W., Daas, L., Suffo, S., Seitz, B., & Abdin, A. D. (2024). First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration. Pharmaceutics, 16(4), 470. https://doi.org/10.3390/pharmaceutics16040470
Vancouver
Aljundi W, Daas L, Suffo S, Seitz B, Abdin AD. First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration. Pharmaceutics. 2024;16(4):470. doi:10.3390/pharmaceutics16040470
BibTeX
@article{Aljundi2024,
author = {Aljundi, Wissam and Daas, Loay and Suffo, Shady and Seitz, Berthold and Abdin, Alaa Din},
title = {First-Year Real-Life Experience with Intravitreal Faricimab for Refractory Neovascular Age-Related Macular Degeneration},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {4},
pages = {470},
doi = {10.3390/pharmaceutics16040470}
}
EUVIMED